Mitochondrial integrity controls cellular and immunological homeostasis in various pathophysiological settings. Recent findings suggest that VDAC2 antagonizes the ability of IFNγ to drive mitochondrial permeabilization in malignant cells by inhibiting BAK, thus promoting cell survival and immunoevasion.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yuan, J. & Ofengeim, D. Nat. Rev. Mol. Cell Biol. 25, 379–395 (2024).
Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T. & Galluzzi, L. Nat. Rev. Immunol. 23, 159–173 (2023).
Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. Cancer Cell 42, 1825–1863 (2024).
Yuan, S. et al. Nat. Immunol. https://doi.org/10.1038/s41586-025-08732-6 (2025).
Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J. & Korsmeyer, S. J. Science 301, 513–517 (2003).
McArthur, K. et al. Science 359, eaao6047 (2018).
Wei, M. C. et al. Science 292, 727–730 (2001).
Beltran-Visiedo, M., Soler-Agesta, R., Sarosiek, K.A., Green, D. R. & Galluzzi, L. Nat. Rev. Mol. Cell Biol. (in the press).
Cosentino, K. et al. Mol. Cell 82, 933–949.e939 (2022).
Acknowledgements
K.C. has been supported by the German Research Foundation (DFG, SFB 1557, P5). Among other sources, L.G. is/has been supported (in various capacities) by the NIH/NCI (R01 CA271915, U54 CA274291), the US DoD BCRP (BC180476P1, BC210945 and W81XWH2120034), and the STARR Cancer Consortium (I16-0064).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting or advisory honoraria from Boehringer Ingelheim, AstraZeneca, AbbVie, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. K.C. and J.V. have no conflicts of interest to declare.
Rights and permissions
About this article
Cite this article
Cosentino, K., Verduijn, J. & Galluzzi, L. VDAC2 enforces a mitochondrial checkpoint to cancer immunity. Nat Immunol 26, 808–809 (2025). https://doi.org/10.1038/s41590-025-02171-1
Published:
Issue date:
DOI: https://doi.org/10.1038/s41590-025-02171-1
